Incannex says Phase 2 trial shows PSX-001 cuts GAD anxiety scores vs placebo

• Incannex highlighted completed Phase 2 results for PSX-001, its oral synthetic psilocybin therapy for generalized anxiety disorder.
• Trial showed meaningful symptom improvement versus placebo, with benefits sustained through 11 weeks.
• Safety profile supported continued development, with no serious adverse events reported.
• Company framed April 18, 2026 White House executive order on serious mental illness as improving regulatory pathway for psychedelics, including potential faster FDA review and rescheduling steps tied to successful Phase 3 completion.
• Incannex reported more than $70 million cash, no debt, as it advances PSX-001 with an active U.S. IND.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-046408), on April 22, 2026, and is solely responsible for the information contained therein.